Effects of intravenous administration of peripheral blood-derived mesenchymal stromal cells after infusion of lipopolysaccharide in horses.

Summary

# Editorial Summary Sepsis remains a major clinical concern in equine practice, with excessive and uncontrolled inflammatory responses driving much of the associated morbidity and mortality; whilst peripheral blood-derived mesenchymal stromal cells (PB-MSC) have shown promise in reducing inflammation in preclinical sepsis models, their therapeutic efficacy in horses had not been systematically evaluated despite evidence of good tolerability. Taylor and colleagues administered allogeneic PB-MSC intravenously to horses following lipopolysaccharide (LPS) challenge—a well-established model of systemic inflammation—to investigate whether cell therapy could modulate the dysregulated immune response characteristic of sepsis. The research team measured inflammatory markers, immune cell populations, and clinical parameters across treatment and control groups to determine whether PB-MSC infusion offered genuine immunomodulatory benefit beyond safety. Findings from this study provide crucial evidence regarding the therapeutic potential (or limitations) of cell-based interventions in equine sepsis, informing whether practitioners should consider PB-MSC as part of future treatment protocols for septic animals. Understanding these mechanisms is particularly valuable for equine vets and internal medicine specialists managing cases of colitis, peritonitis, or other conditions where systemic inflammation becomes life-threatening.

Read the full abstract on PubMed

Key Findings

• •Allogeneic peripheral blood-derived mesenchymal stromal cells (PB-MSC) administered intravenously to horses are well-tolerated
• •PB-MSC mitigate inflammation in animal models of sepsis
• •Therapeutic benefits of IV PB-MSC in horses remain unknown despite good tolerability

Conditions Studied

Tags